What the new PRAME data means for Immatics stock Fresh clinical results for Immatics (NasdaqCM:IMTX) are in focus after updated Phase 1b IMA402 and Phase 1 IMA203CD8 data in PRAME expressing solid tumors were shared at the 2026 ESMO meeting. The readout centers on heavily pretreated melanoma and ovarian cancer patients, where Immatics reported objective responses, disease control and durability signals, alongside what management described as manageable safety profiles for both...
Detailed price information for Immatics NV (IMTX-Q) from The Globe and Mail including charting and trades.
Immatics (IMTX) said Tuesday that it has agreed to sell 12,945,916 ordinary shares at $8.69 each, an
This is the newest page. Registered accounts read further back.